About
Sonodymanic Therapy for Brain Cancer
Areas of Focus
Categories
Uncategorized Medical DeviceMidwest
Team (8)
Ann-Marie Hulstine
VP, Clinical Operations
Alpheus Medical
executive
David Reardon
Professor, Medicine, Harvard Medical School; Clinical Director, Center for Neuro-Oncology, Medical Oncology, Dana-Farber Cancer Institute.
Alpheus Medical
team_member
Imran Eba
Chief Financial Officer
Alpheus Medical
executive
Jeremy Ling
Chief Technology Officer
Alpheus Medical
executive
Nick Ellens
VP, Research & Development
Alpheus Medical
executive
Roger Stupp
Chief of Neuro-oncology, Professor of Neurological Surgery, Medicine and Neurology, Feinberg School of Medicine at Northwestern University.
Alpheus Medical
team_member
Clinical Trials (2)
View allTotal Trials
2
As Lead Sponsor
1
As Collaborator
1
Total Enrollment
36
By Phase
PHASE1: 2
By Status
RECRUITING: 1COMPLETED: 1
Clinical Trials Pipeline2 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2021
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT06665724Collaborator
Clinical Trial Evaluating Safety of 5-Aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy (SDT) in Patients With Newly Diagnosed High-Grade Glioma (HGG) Prior to Resection and Standard Adjuvant Therapy (ALA SDT GLIOMA 401)
PHASE1Recruiting
14 participants
Started: Jan 27, 2025 · Completed: Mar 31, 2026
NCT05362409Lead Sponsor
Study to Evaluate 5-ALA Combined With CV01 Delivery of Ultrasound in Recurrent High Grade Glioma
PHASE1Completed
22 participants
Started: Jun 29, 2022 · Completed: Feb 3, 2025
Locations (1)
Headquarters
Chanhassen, MN, United States
Map
Loading map...